Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
News for 60 Degrees Pharmaceuticals, Inc. (warrants: SXTPW) centers on its activities as a pharmaceutical company focused on developing and commercializing medicines for vector-borne diseases. Company announcements repeatedly highlight work in malaria prevention through its FDA-approved product ARAKODA (tafenoquine), as well as clinical research programs in babesiosis, an emerging tick-borne illness for which no FDA-approved treatment currently exists.
Investors and observers following SXTPW-related news will see updates on clinical trial milestones, including the B-FREE Chronic Babesiosis Study (NCT06656351) and other tafenoquine studies in hospitalized and relapsing babesiosis patients. Releases describe study designs, enrollment progress, and early findings such as Babesia detection rates in chronic fatigue cohorts or parasite status in individual patients completing treatment regimens.
Company news also covers commercial and marketing developments for ARAKODA, such as expansion of inside sales teams, partnerships with platforms like GoodRx to broaden offer visibility, and digital marketing campaigns aimed at prescribers. Financial updates, including quarterly results and commentary on product demand trends, appear alongside these operational highlights.
Regulatory and capital markets items form another important news category. Examples include announcements of reverse stock splits intended to support continued Nasdaq listing, at-the-market sales agreements for common stock, and participation in investor conferences where management presents the company’s vector-borne disease strategy.
For readers tracking SXTPW, the news stream offers a view into how 60 Degrees Pharmaceuticals advances its malaria franchise, builds a babesiosis clinical program, manages its Nasdaq-listed securities, and collaborates with academic and research institutions in the U.S. and Australia. Bookmark this page to follow ongoing disclosures about trials, regulatory interactions, financing transactions, and other material events tied to the company’s warrants and underlying common stock.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), a pharmaceutical company focused on vector-borne disease treatments, has announced an updated schedule for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation, and the management team will be available for one-on-one meetings during the conference. The presentation will be accessible via webcast for interested investors.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a company focused on developing medicines for vector-borne diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation on September 10 at 2:30 ET. Management will also conduct one-on-one meetings during the conference. The presentation will be available via webcast with replay access for approximately 90 days on the company's investor relations website.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has selected the Icahn School of Medicine at Mount Sinai as the central site for a Phase II clinical trial evaluating tafenoquine for chronic babesiosis treatment. The 90-day open-label study will assess the drug's efficacy in treating patients with disabling fatigue lasting at least six months.
The trial will evaluate ARAKODA® (tafenoquine) with a dosing regimen of 2 x 100 mg tablets administered orally for the first four days, followed by weekly doses for 12 weeks. The primary endpoint is fatigue resolution measured using a patient-reported outcome scale. Enrollment is expected to begin in Q4 2025 with completion targeted for Q2 2026.
This study is one of three clinical trials sponsored by 60 Degrees Pharma to evaluate tafenoquine for babesiosis, with data expected in H1 2026. The company plans to submit a New Drug Application (NDA) to the FDA in 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2025 financial results, highlighting a 19% year-over-year decline in net product revenues to $101,000 due to a temporary supply chain disruption. Despite lower revenues, the company achieved increased profitability with a gross profit of $51,000, up from $35,000 in Q2 2024.
Operating expenses decreased significantly to $1.86 million from $4.22 million in Q2 2024. The net loss improved to $1.84 million ($1.25 per share) compared to $4.29 million ($21.12 per share) in Q2 2024. With $1.97 million cash on hand and recent public offering proceeds of $4.46 million, the company projects runway through March 31, 2026.
Research studies indicate the total addressable U.S. market for ARAKODA for human babesiosis could reach $1.1 billion over the remaining 10-year patent life, with annual babesiosis incidence estimated between 25,000-380,000 cases.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has entered into a research agreement with Tulane University to study tafenoquine's effectiveness against Borrelia (Lyme disease) and Bartonella bacteria in cell culture. These pathogens, along with Babesia, are known as the "3Bs" commonly found in tick-borne illnesses.
The study aims to evaluate tafenoquine, an FDA-approved antimalarial drug marketed as ARAKODA®, for potential treatment of co-infections in babesiosis patients. Currently, tafenoquine is undergoing babesiosis trials at several sites. The drug's safety for malaria prophylaxis has been validated through six randomized, controlled trials lasting up to 12 months, though it remains unapproved for treating babesiosis, Borrelia, or Bartonella infections.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has closed its previously announced public offering, raising $5 million in immediate gross proceeds. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) with accompanying Series A-1 and A-2 warrants at $1.90 per share.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. If the Series A-2 warrants are fully exercised, the company could receive up to an additional $5 million in gross proceeds. H.C. Wainwright & Co. served as the exclusive placement agent, and the proceeds will be used for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has announced the pricing of a $5 million public offering with potential additional proceeds of up to $5 million through warrant exercises. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) at $1.90 per share, along with Series A-1 and A-2 warrants.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. H.C. Wainwright & Co. is serving as the exclusive placement agent, with closing expected around July 16, 2025. The company plans to use proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced the potential market size for ARAKODA® (tafenoquine) in treating human babesiosis, projecting maximum annual sales of $245 million and a cumulative market value of $1.1 billion through patent expiration in 2035.
The market assessment is based on comprehensive research including a 6,000-patient nationwide survey and feedback from 300 healthcare professionals. The company estimates a total addressable market of 380,000 patients annually.
Currently, three clinical trials are underway or planned to evaluate tafenoquine's safety and efficacy. The company expects to submit a New Drug Application (NDA) to the FDA in 2026, pending positive trial results.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced plans to submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. The submission will be supported by three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, including one company-sponsored study at North Carolina State University.
The studies demonstrated that tafenoquine was well-tolerated and effective in treating both experimental and naturally acquired Babesia infections in dogs. This development is significant as there are currently no FDA-approved oral treatments for canine babesiosis, an emerging tick-borne illness that affects hundreds to thousands of dogs annually in the United States.